Introduction
Current epidemiological data suggest patients with diabetes have an increased risk of developing different types of cancer [1, 2] ; in addition, there are reports of certain cancers developing more commonly in patients with type 2 diabetes [2] . Several types of cancer have been associated with obesity [2] , as well as with type 2 diabetes; for example, breast cancer [2, 3, 4] , endometrial cancer [2, 5, 6] , pancreatic cancer [2, 4] , and colorectal cancer [2, 4, 7] . Insulin resistance and hyperinsulinemia may promote carcinogenesis either directly through the Mirosława Polaszewska-Muszyńska, Centre for Diabetes and Endocrinology in Bydgoszcz, 17 Baczyńskiego Street, 85-822 Bydgoszcz, Poland, tel: (0048)604230799, fax: +48523726350, e-mail: mmuszynska@poczta.onet.pl  PRACE ORYGINALNE insulin receptor or indirectly by increasing the levels of insulin-like growth factors (IGF). Understanding the relationship between diabetes and cancer, and their associated comorbidities and complications, may have important implications for the prevention and management of these disorders [1, 8, 9] .
There are many means by which type 2 diabetes is currently treated. A drug commonly used as an initial and combined therapy is metformin [2] , which reduces levels of circulating glucose and insulin in patients who suffer from hyperinsulinaemia caused by insulin resistance [2] . The primary mode of action of metformin is through reduced hepatic glucose output [2, 10] . Madiraju et al. showed that the mechanism of action included the following: delayed intestinal glucose absorption, enhanced release of glucagon-like peptide 1, augmented lactate production by enterocytes, and activation of AMP-activated protein kinase in hepatocytes as a result of decreased energy charge, as well as inhibition of glucagon signalling, glycolytic enzymes, transcription of gluconeogenic enzymes, or mitochondrial complex I [11, 12] .
Medications used for the treatment of hyperglycaemia may either increase or reduce the risk of developing cancer [2] . Metformin is widely used in patients with type 2 diabetes and has been shown to reduce the risk of cancer in those patients -both in small-scale studies [13] and in the multicentre randomised controlled UK Prospective Diabetes Study [14] . Not all agree on this association: a large, retrospective, population-based study using information from the healthcare databases in Ontario, Canada, failed to confirm the association between metformin treatment and reduced risk of prostate cancer in elderly men with diabetes [15] . Importantly, the study acknowledges the differences in study population characteristics to other work [15] , and states that the populations in which the metformin effect on cancer risk was not observed were older, comorbid, and had worse grade distribution than most prostate cancer cohorts (contemporary cancer cohorts) [15] . It is possible that in a younger cohort metformin used for the treatment of type 2 diabetes may have a positive effect on cancer risk [15] .
The aim of the study was to assess the influence of treatment with metformin on the prevalence of cancer in patients with type 2 diabetes, and to assess risk factors, by comparing clinical characteristics of patients with cancer and those without cancer.
Materials and methods

Study population
A total of 1063 patients treated in the Diabetes and Endocrinology Centre in Bydgoszcz, who were involved in the national health program "Comprehensive Specialist Outpatient Care" (in Polish: Kompleksowa Ambulatoryjna Opieka Specjalistyczna -KAOS), were enrolled in the retrospective study. The program is provided by the Polish national health care system to patients with chronic diseases, including those with type 1 diabetes, type 2 diabetes requiring insulin, and gestational diabetes. The aim of this program is to standardise specialist care of patients with chronic diseases and to secure the best patient management. In the case of patients with diabetes, the program covers a wide spectrum of specialist consultants.
Only patients who were first diagnosed with diabetes and consecutively with cancer were included in the analysis. As such, 20 patients for whom the diagnosis of cancer was reported before the onset of diabetes were excluded, as were 15 patients without a date of diagnosis of cancer. Patients for whom multiple cancers were reported were included in the study only once. The final dataset for analysis compromised data from 1028 patients with type 2 diabetes, for whom the association between cancer occurrence and treatment (with or without metformin) was analysed. The patient population was divided into two groups: with cancer and without cancer.
Patient data
The following data were collected: -Demographics and medical history: age, sex, duration of diabetes, and comorbidities (e.g. 
Study timeframe
All study visits took place between October 2012 and March 2013.
Ethics
The study was conducted after obtaining permission from the Ethics Committee, in accordance with Polish Law and appropriate EU regulations on non-interventional studies.
Statistics
The statistical data are reported as the number of patients (n), mean (SD), median (IQR), or percentage. Comparisons of the data between patients with and without cancer were performed using a Student's t-test (for numeric variables) and Chi-square test with Yates' continuity correction (for categorical variables). Multiple logistic regression was used to examine the relationship between treatment (with or without metformin) and cancer incidence, age at study visit, and metformin use. P-values less than or equal to 0.05 were considered statistically significant.
Results
Characteristics of study population
The mean age of 1028 analysed patients was 67.9 years (SD 8.84 years). Women constituted 51% and men 49% of the study population. The differences between the men and women in the study population are shown in Table I .
Overall, the mean duration of diabetes was 16.8 years (SD 7.54 years); the average patient weight was 86.7 kg (SD 15.2 kg), and the mean body mass index (BMI) was 31.7 kg/m 2 (SD 5.08 kg/m 2 ). Of all enrolled patients, 46% had retinopathy, 20.8% polyneuropathy, 9.5% diabetic foot, 7.7% nephropathy, and 2.6% carotid atherosclerosis. In terms of treatments, 77.8% were treated with statins, 69.9% with beta-blockers, 66% with acetylsalicylic acid, 42% with thiazides, 38.1% with Ca-blockers, 11% with fibrates, and 3% with alpha-blockers. The mean HbA 1c in the total study population was 8.1% (SD 1.31%). The mean glomerular filtration rate was 68.2 mL/min. 
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Cancer population
Of the total patient population, ~10% (110 patients) were reported to have cancer, with 115 cases of cancer reported. In one patient three cancer occurrences were reported, and in three patients two cancer occurrences were reported. The most commonly observed cancer was breast cancer (24 patients; 22.5%), followed by uterine cancer (15 patients; 13.6%). Eleven patients (10%) were diagnosed with colon cancer, and another 10% with prostate cancer. The cancer types observed in our study population are summarised in Table II .
Comparison of patients with and without cancer
The time from onset of diabetes to the diagnosis of cancer in patients treated with metformin (n = 14) was 9.6 years (SD 5.67 years); the time from onset of diabetes to the first study visit in patients without cancer treated with metformin (n = 362) was 15.6 years (SD 6.55 years). The corresponding data for patients who did not receive metformin was 13.7 years (SD 6.99 years) for patients who developed cancer (n = 61), and 17.3 years (SD 8.02 years) for patients who did not develop cancer (n = 591). Differences between patients with and without cancer were found when comparing diabetes duration and age at last follow-up (p < 0.05). When comparing the groups in terms of age at diabetes onset, diastolic and systolic blood pressure, BMI, or HbA1c, no differences were observed (Table III) . When comparing complications of diabetes, no differences were observed (Table IV) .
Analysis of metformin treatment and risk of cancer
Of the 75 diabetic patients with a cancer diagnosis, 18.7% were treated with metformin; whereas, 38% of the 953 patients without cancer received metformin. An analysis of metformin treatment and cancer development is shown in Table V . Additionally, the negative association between age at study visit and use of metformin was identified (estimate: -0.043; p < 0.0001).
Risk of cancer
Using only patients with complete follow-up information and a positive follow-up time, multiple logistic regression showed metformin treatment had a significant positive effect on cancer incidence (p = 0.006). In addition, this analysis indicated that the longer the duration of diabetes, the greater the risk of cancer (p = 0.032) and that the use of acetylsalicylic acid (p = 0.002) ( Table VI) . The age of diabetes onset, gender, and BMI did not prove to be predictors of cancer, nor did HbA 1c level, acetylsalicylic acid dose, non-proliferative retinopathy, proliferative retinopathy, diabetic foot, carotid atherosclerosis, polyneuropathy and nephropathy, or anticoagulant therapy (Table VI) . Analysis using Kaplan-Meier curves showed that the probability of developing cancer was higher in patients who were not treated with metformin, compared to those who were (p = 0.006; Fig. 1) .
Discussion
In the current study, we observed metformin to have a protective effect in patients with type 2 diabetes, specifically by preventing the development of cancer. The study was performed in patients who were under strict professional control because they belonged to the Comprehensive Outpatient Specialist Care program. Our findings are supported by a comparison of metformin-treated and untreated patients, as well as by multiple logistic regression. Our Kaplan-Meier curves also showed that the risk of developing cancer was higher in patients who
were not treated with metformin. This observation is in line with the currently understood mechanism of action of metformin. 
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Metformin is likely to inhibit cell proliferation and reduce colony formation, as shown in in vitro studies of cancer cell lines [2, [17] [18] [19] . It induces muscles to take up glucose from the blood through targeting of the AMP-activated protein kinase (AMPK). The mechanism is also known to be dependent on the activation of the protein kinase LKB1 -a tumour suppressor [13] . It is probable that this correlation is beneficial in the primary and secondary prevention of certain types of cancers [13] . It is most probable that the influence of metformin on LKB1 or AMPK is secondary to its effect on mitochondria, which are the primary target of the drug [20] . The intensive glucose control observed following metformin treatment appeared to reduce the risk of diabetes-related health complications (including death) when compared to insulin and sulfonylureas [20] . Metformin may show a prevention role of cancer [21] . Metformin-induced activation of AMPK in tumour cells is suggested to lead to inhibition of cell growth, at least in part by inhibiting protein synthesis [2] . Another mode of action of metformin might be through an AMPK-mediated regulation of fatty acid synthesis. Prostate, breast, and colon cancers cells constitutively over-express fatty acid synthase, which is a key enzyme for de novo fatty acid biosynthesis, and has been associated with the malignant phenotype. Another potential mechanism is based on the positive impact of metformin on chronic inflammation. Metformin not only inhibits the proliferation of cancer cells, it also promotes cell death of these same cells by activating apoptotic pathways. It has also been suggested that metformin can inhibit the growth of cancer cells by decreasing their energy status and forcing a metabolic conversion that cancer cells are unable to execute [21] .
Results of other observational human studies also indicate that therapy with metformin is associated with reduced risk of cancer [2, 13, [22] [23] [24] and cancer morta lity [2, 25] . Observational data suggest metformin might improve cancer prognosis as well [2] .
Type 2 diabetes is associated with increased risk of cancer affecting the breast, colon, prostate, kidney, and pancreas [2, 21] . The most common type of cancer observed in patients in our study population was breast cancer, which is similar to the observations of Giovanucci et al. [2] , Michels et al. [3] , and Coughlin et al. [4] . Other common cancers included uterine cancer, colon cancer, and prostate cancer. A number of studies have discussed the mechanisms underlying the relationship between diabetes and cancer; however, a metabolic or biochemical reliance is thought to be key. The association between the two diseases appears to be mediated through the metabolic system [1] . Both diseases, which are likely to be biologically linked through an as-yet--unknown mechanism, share the range of potential risk factors: both modifiable and non-modifiable [2] . Non--modifiable risk factors are: age, gender, and ethnicity; whereas, modifiable risk factors are: weight, obesity, weight change, diet, physical activity, smoking status, and alcohol consumption [2] . In the current study, we did not observe any relationship between BMI and risk of cancer development. It has been observed that both the occurrence of cancer and diabetes increase with age and gender: men have a slightly higher age-adjusted risk of diabetes than women [2] . In the current study, gender did not influence the risk of cancer development.
The incidence of tumours in the current study was almost twice that recently reported for the general Polish population of patients with type 2 diabetes (5.9%) [26] . This result can be explained by the nature of the patients included in the Comprehensive Outpatient Specialist Care program when compared with the general population; specifically, patients included in this program are at a more advanced disease stage but, at the same time, they are subjected to more thorough care with better screening of other comorbid diseases. In addition, the observed incidence of the individual tumours is a little different, and may be explained by differences between study populations (for example, diabetes duration). Like the authors of other studies, we did not observe a correlation between the incidence of cancer and the degree of glycaemic control (as measured by glycated haemoglobin levels), weight, or duration of diabetes. Perhaps such a relationship would be able to be observed for individual types of cancer, but the study would require a larger population.
The results of our study should be interpreted with caution, in light of the retrospective nature of the study. We did not have the exact date of metformin implementation, and assumed that metformin had been administered very early in the course of diabetes; that is, that the duration of diabetes was equal to the duration of treatment with metformin. Moreover, we did not have information about other risk factors for cancer development, such as family history or lifestyle parameters. Another limitation of our study was the fact that our population differed from the general population with type 2 diabetes. First of all, the patients covered by the Comprehensive Outpatient Specialist Care program suffered from more advanced type 2 diabetes, and appeared to have more problems with controlling the disease, as indicated by an increased HbA 1c value. The mean HbA 1c in our study was slightly higher than in the patient population reported by Sieradzki et al.
(mean HbA 1c -7.7%), who nevertheless postulated the need for earlier and more intensive treatment [27] . Therefore, we would like to reiterate that our findings are specific to the population of patients with more severe and poorer controlled type 2 diabetes compared to the overall population. Finally, we should underline that the negative association between metformin use and age could at least partly contribute to the observed association between metformin use and the likelihood of cancer. The association between metformin use and age was weak, and that is why we would consider it as a minor confounder. All of these facts need to be taken into account when interpreting the results of our study.
Conclusions
To conclude, as suggested by many observational studies, therapy with metformin reduces the risk of cancer. In our trial, the protective effect of metformin was confirmed. These results are of high clinical significance becuase metformin is widely used, generally well tole rated, and commonly accepted. Long-term observational trials in larger group of patients should be performed, and they will be crucial in directing future research.
